LigaChem Biosciences Inc. (141080.KQ) Stock

141080.KQ logo

LigaChem Biosciences Inc.

141080.KQSouth Korea
Healthcare

Company profile

LigaChem Biosciences reported revenue of 125.90 billion KRW for fiscal year 2024. In Q2 2025 (the quarter ended June 30, 2025) revenue was 32.62 billion KRW. Its largest business segment, New Drug Research and Development, brought in 86% of segment revenue in fiscal year 2024. In Q2 2025 it reported a net loss of 30.55 billion KRW, against a net loss of 7.45 billion KRW a year earlier. Our analysis of its filings shows revenue growing from 33.41 billion KRW in fiscal year 2022 to 125.90 billion KRW in fiscal year 2024, 94.1% a year on average. LigaChem Biosciences reports about 183 full-time employees.

What stands out

  • Revenue more than tripled (up 268.7%) in fiscal year 2024, from 34.15 billion KRW in fiscal year 2023, after a rise of 2.2% the year before.
  • Its net profit margin over the last four reported quarters was -180.9%, against a median of 4.7% for 6 listed companies of similar size in its industry.
  • It returned to a profit in fiscal year 2024, 7.80 billion KRW, after 4 years of net losses (73.70 billion KRW in fiscal year 2023).
  • Revenue growth slowed in Q2 2025: up 6.1% from a year before.

Figures from company filings; latest fiscal year ended December 31, 2024.

About LigaChem Biosciences Inc.

LigaChem Biosciences Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of medicines for unmet medical needs. The company researches and develops products for various therapeutic areas, including antibiotics, anti-fibrotics, immuno-oncology, oncology; and antibody-drug conjugate (ADC) platform technology and small molecule drugs. It also sells medical device and supplies. It has a research collaboration and license agreement with AMGEN for the development and commercialization of ADCs. The company was formerly known as LegoChem Biosciences, Inc. and changed its name to LigaChem Biosciences Inc. in April 2024. LigaChem Biosciences Inc. was founded in 2006 and is headquartered in Daejeon, South Korea.

Largest shareholders

  • Orion Corp.27.13%
  • National Pension Service of Korea5.96%
  • The Korea Development Bank (Investment Management)3.67%
  • Yong-Zu Kim3.361 %3.36%
  • Se-Jin Park0.4904 %0.49%

Share of the company, as of September 25, 2026

Leadership

  • Sejin Park M.B.A. — CEO, President & Director, 63
  • Jeiwook Chae Ph.D. — Senior VP, Head of R&D and CEO of ACB
  • Young-Lag Cho Ph.D. — Senior VP & Chief Development Division
  • Rodrigo Ruiz Soto M.D. — Chief Medical Officer
  • Chul-Woong Chung Ph.D. — MD & Head of the ADC Research Institute

How much revenue does LigaChem Biosciences make?

LigaChem Biosciences reported 125.90 billion KRW in revenue for fiscal year 2024, up 268.7% from 34.15 billion KRW in fiscal year 2023. In Q2 2025 revenue was 32.62 billion KRW.

What is LigaChem Biosciences's largest business segment?

New Drug Research and Development, with 121.16 billion KRW or 86% of segment revenue in fiscal year 2024. Next: Pharmaceutical Business (14%).

What companies are similar to LigaChem Biosciences?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Yuhan Corporation (000100.KS), Hanmi Pharm. Co., Ltd. (128940.KS), Hanall Biopharma Co., Ltd. (009420.KS), Hugel, Inc. (145020.KQ).

How has LigaChem Biosciences' revenue changed over the last 5 fiscal years?

Revenue by fiscal year: FY2020, 49.39 billion KRW; FY2021, 32.16 billion KRW; FY2022, 33.41 billion KRW; FY2023, 34.15 billion KRW; FY2024, 125.90 billion KRW.

How does LigaChem Biosciences' profit margin compare with similar companies?

Net profit margin over the last four reported quarters: LigaChem Biosciences, -180.9%; Yuhan Corporation (000100.KS), 10.4%; Hanmi Pharm. Co., Ltd. (128940.KS), 0.0%; Hanall Biopharma Co., Ltd. (009420.KS), -15.3%; Hugel, Inc. (145020.KQ), 26.4%; Celltrion Pharm, Inc. (068760.KQ), 9.5%; OliX Pharmaceuticals, Inc (226950.KQ), -102.9%.

Company Information

SectorHealthcare
IndustryMulti-Therapeutic Drug Manufacturing
Employees183
HeadquartersDaejeon, South Korea
ExchangeKOSDAQ
TimezoneAsia/Seoul (KST)

Contact & Links

Address
10, Gukjegwahak 10-ro, Daejeon, 34002
Phone
82 4 2861 0688
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “LigaChem Biosciences Inc. (141080.KQ)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/141080.KQ

LinkedInLinkedInXXYouTubeYouTube